Research
Greater lean-body-mass decline with tirzepatide than semaglutide in routine care, revealed by body-composition digital phenotyping
Nature ·
The Brief
- A study reports greater lean-body-mass decline with tirzepatide than with semaglutide in routine care.
- The comparison was made using body-composition digital phenotyping.
- The source provided is a nature.com subject feed entry with no summary.
Why it matters
Loss of lean mass during weight-loss treatment is a clinically relevant side effect, so a head-to-head comparison of two widely used drugs in routine care is useful for clinicians and patients.
Who’s affected
- clinicians prescribing GLP-1 receptor agonists
- patients using tirzepatide or semaglutide
- #tirzepatide
- #semaglutide
- #lean mass
- #obesity drugs
- #body composition
Timeline
Study published in Medical research (nature.com)
Medical research : nature.com subject feeds
Greater lean-body-mass decline with tirzepatide than semaglutide in routine care, revealed by body-composition digital phenotyping